1. Scrip
  2. >>Advanced Therapies

CG Oncology Is Building A Best-In-Class Profile In NMIBC

Cretostimogene Phase III Data Look Competitive

 
• By Joseph Haas

The biotech’s Phase III data with an oncolytic immunotherapy for non-muscle invasive bladder cancer shows high complete response rates, duration of response and good safety/tolerability.

CG Oncology's Phase III data look competitive in high-risk bladder cancer (Shutterstock)

CG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data could position it as a best-in-class therapy for high-risk non-muscle invasive bladder cancer (NMIBC) compared to a competing Phase III candidate from Johnson & Johnson, as well as Merck & Co.’s Keytruda (pembrolizumab).

Key Takeaways
  • CG Oncology sees additional Phase III data for cretostimogene as bolstering its case that the oncolytic immunotherapy is a best-in-class therapy for non-muscle invasive bladder cancer.

The company presented data from the Phase III BOND-003 monotherapy trial on 5 December at the Society of Urologic Oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Advanced Therapies

Sarepta Expects Tighter Elevidys Label As Amondys/Vyondys Study Sputters

 
• By Alaric DeArment

The company’s third quarter earnings fell by $67.8m year-over-year, reflecting the tumultuous situation around its DMD therapy Elevidys in June.

UniQure Reeling As FDA Reverses Stance On Accelerated Approval For AMT-130

 
• By Joseph Haas

UniQure’s plan for a 2026 BLA filing of gene therapy AMT-130 for Huntington’s is uncertain, as the FDA apparently reversed course after indicating it would consider accelerated approval.

BioMarin Looks To Offload Roctavian As Gene Therapy’s Sales Drop

 
• By Alaric DeArment

The company said in its third quarter earnings that it would focus on areas that better foster growth for the company as the hemophilia A treatment only brought in $3m in Q3.

Intellia Hits Pause On Phase III Nex-z Studies After Second Liver Enzyme Event

 
• By Alaric DeArment

The company reported that a patient went to the emergency room after experiencing grade 4 transaminase elevations, which unlike a similar event in May caused symptoms.

More from Therapy Areas

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.